دورية أكاديمية
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden.
| العنوان: | Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden. |
|---|---|
| المؤلفون: | Rögnvaldsson S; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Landspítali - The National University Hospital of Iceland, Reykjavík. srognvald@hi.is., Thorsteinsdóttir S; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Rigshospitalet, Copenhagen, Denmark., Syriopoulou E; Karolinska Institutet, Stockholm, Sweden; Red door analytics AB, Stockholm., Sverrisdottir I; Sahlgrenska University Hospital, Gothenburg., Turesson I; Skåne University Hospital, Lund., Eythorsson E; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Landspítali - The National University Hospital of Iceland, Reykjavík., Oskarsson JT; Faculty of Medicine, University of Iceland, Reykjavík., Long TE; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Skåne University Hospital, Lund., Vidarsson B; Landspítali - The National University Hospital of Iceland, Reykjavík., Onundarson PT; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Landspítali - The National University Hospital of Iceland, Reykjavík., Agnarsson BA; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Landspítali - The National University Hospital of Iceland, Reykjavík., Sigurdardottir M; Landspítali - The National University Hospital of Iceland, Reykjavík., Olafsson I; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Landspítali - The National University Hospital of Iceland, Reykjavík., Thorsteinsdottir I; Landspítali - The National University Hospital of Iceland, Reykjavík., Aspelund T; Faculty of Medicine, University of Iceland, Reykjavík., Gislason GK; Faculty of Medicine, University of Iceland, Reykjavík., Olafsson A; Faculty of Medicine, University of Iceland, Reykjavík., Sigurdsson JK; Faculty of Medicine, University of Iceland, Reykjavík., Hultcrantz M; Myeloma Service, Dept. of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY., Durie BGM; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA., Harding S; Binding Site Group Ltd., Birmingham, United Kingdom., Bjorkholm M; Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Stockholm., Landgren O; Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami., Love TJ; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Landspítali - The National University Hospital of Iceland, Reykjavík., Kristinsson SY; Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Landspítali - The National University Hospital of Iceland, Reykjavík. |
| المصدر: | Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2250-2255. Date of Electronic Publication: 2024 Jul 01. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1999- : Pavia, Italy : Ferrata Storti Foundation Original Publication: Pavia [etc.] |
| مواضيع طبية MeSH: | Monoclonal Gammopathy of Undetermined Significance*/epidemiology , Monoclonal Gammopathy of Undetermined Significance*/diagnosis, Humans ; Iceland/epidemiology ; Sweden/epidemiology ; Male ; Female ; Middle Aged ; Aged ; Risk Factors ; Multiple Myeloma/epidemiology ; Multiple Myeloma/diagnosis ; Multiple Myeloma/etiology ; Neoplasms/epidemiology ; Neoplasms/etiology ; Neoplasms/diagnosis ; Disease Progression ; Adult ; Population Surveillance |
| مستخلص: | There is some evidence that a prior cancer is a risk factor for the development of multiple myeloma (MM). If this is true, prior cancer should be associated with a higher prevalence or increased progression rate of monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM and related disorders. Those with a history of cancer might therefore constitute a target population for MGUS screening. This two-part study is the first study to evaluate a relationship between MGUS and prior cancers. First, we evaluated whether prior cancers were associated with having MGUS at the time of screening in the Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) study that includes 75,422 individuals screened for MGUS. Next, we evaluated the association of prior cancer and the progression of MGUS to MM and related disorders in a population-based cohort of 13,790 Swedish individuals with MGUS. A history of prior cancer was associated with a modest increase in the risk of MGUS (odds ratio=1.10; 95% confidence interval: 1.00-1.20). This excess risk was limited to prior cancers in the year preceding MGUS screening. A history of prior cancer was associated with progression of MGUS, except for myeloid malignancies which were associated with a lower risk of progression (hazard ratio=0.37; 95% confidence interval: 0.16-0.89; P=0.028). Our findings indicate that a prior cancer is not a significant etiological factor in plasma cell disorders. The findings do not warrant MGUS screening or different management of MGUS in those with a prior cancer. |
| References: | Haematologica. 2023 Dec 01;108(12):3392-3398. (PMID: 37439374) Blood. 2009 May 28;113(22):5412-7. (PMID: 19179464) Blood. 2003 Nov 15;102(10):3759-64. (PMID: 12881316) Br J Cancer. 2011 Jul 26;105(3):460-5. (PMID: 21772332) Lancet. 2020 Mar 28;395(10229):1078-1088. (PMID: 32222192) Scand J Public Health. 2020 Feb;48(1):1-4. (PMID: 31985364) Blood Cancer J. 2021 May 17;11(5):94. (PMID: 34001889) Eur J Hum Genet. 2022 Apr;30(4):474-479. (PMID: 34845334) Acta Oncol. 2012 Sep;51(7):880-9. (PMID: 22974093) J Clin Oncol. 2011 Feb 10;29(5):573-82. (PMID: 21220604) Ann Hematol. 2014 Jan;93(1):157-62. (PMID: 24381068) Haematologica. 2022 Jan 01;107(1):284-286. (PMID: 34474548) Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):88-92. (PMID: 21454200) N Engl J Med. 2006 Mar 30;354(13):1362-9. (PMID: 16571879) JAMA Oncol. 2015 Nov;1(8):1061-8. (PMID: 26335650) Eur J Haematol. 2021 Apr;106(4):529-536. (PMID: 33455012) Nat Rev Drug Discov. 2019 Nov;18(12):899-900. (PMID: 31780841) Blood. 2008 Oct 15;112(8):3052-6. (PMID: 18703425) Cancers (Basel). 2021 Feb 05;13(4):. (PMID: 33562441) Cancers (Basel). 2022 Jan 26;14(3):. (PMID: 35158895) Ann Transl Med. 2020 May;8(10):638. (PMID: 32566575) Blood Adv. 2017 Nov 01;1(24):2186-2192. (PMID: 29296866) Int J Cancer. 2007 Nov 15;121(10):2260-6. (PMID: 17583571) Lancet. 2010 May 15;375(9727):1721-8. (PMID: 20472173) |
| معلومات مُعتمدة: | P30 CA240139 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20240111 Date Completed: 20240701 Latest Revision: 20240817 |
| رمز التحديث: | 20240818 |
| مُعرف محوري في PubMed: | PMC11215371 |
| DOI: | 10.3324/haematol.2023.284365 |
| PMID: | 38205512 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1592-8721 |
|---|---|
| DOI: | 10.3324/haematol.2023.284365 |